147 related articles for article (PubMed ID: 36587736)
1. Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant Pseudomonas aeruginosa to cefiderocol.
Devoos L; Biguenet A; Rousselot J; Bour M; Plésiat P; Fournier D; Jeannot K
Clin Microbiol Infect; 2023 May; 29(5):652.e1-652.e8. PubMed ID: 36587736
[TBL] [Abstract][Full Text] [Related]
2. Performance of disc diffusion, MIC gradient tests and Vitek 2 for ceftolozane/tazobactam and ceftazidime/avibactam susceptibility testing of Pseudomonas aeruginosa.
Daragon B; Fournier D; Plésiat P; Jeannot K
J Antimicrob Chemother; 2021 Sep; 76(10):2586-2592. PubMed ID: 34245282
[TBL] [Abstract][Full Text] [Related]
3. Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in
Jeannot K; Gaillot S; Triponney P; Portets S; Pourchet V; Fournier D; Potron A
Microorganisms; 2023 Jul; 11(8):. PubMed ID: 37630529
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
[TBL] [Abstract][Full Text] [Related]
5. Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales.
Bonnin RA; Emeraud C; Jousset AB; Naas T; Dortet L
Clin Microbiol Infect; 2022 Aug; 28(8):1156.e1-1156.e5. PubMed ID: 35533970
[TBL] [Abstract][Full Text] [Related]
6. Performance of Ceftolozane-Tazobactam Etest, MIC Test Strips, and Disk Diffusion Compared to Reference Broth Microdilution for β-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Magnano P; Wong-Beringer A; Tibbetts R; Miller SA
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29212704
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.
Matuschek E; Longshaw C; Takemura M; Yamano Y; Kahlmeter G
J Antimicrob Chemother; 2022 May; 77(6):1662-1669. PubMed ID: 35289853
[TBL] [Abstract][Full Text] [Related]
9. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
10. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
[TBL] [Abstract][Full Text] [Related]
11. Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria.
Dortet L; Niccolai C; Pfennigwerth N; Frisch S; Gonzalez C; Antonelli A; Giani T; Hoenings R; Gatermann S; Rossolini GM; Naas T
J Antimicrob Chemother; 2023 Jul; 78(7):1672-1676. PubMed ID: 37209112
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp.
Matuschek E; Åhman J; Webster C; Kahlmeter G
Clin Microbiol Infect; 2018 Aug; 24(8):865-870. PubMed ID: 29221995
[TBL] [Abstract][Full Text] [Related]
13.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Lagacé-Wiens PRS; Schweizer F; Bay D; Lynch JP; Mulvey MR; Zhanel GG
Microbiol Spectr; 2022 Aug; 10(4):e0172422. PubMed ID: 35758747
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia.
Kostoulias X; Chang CC; Wisniewski J; Abbott IJ; Zisis H; Dennison A; Spelman DW; Peleg AY
Pathology; 2023 Aug; 55(5):663-668. PubMed ID: 37336685
[TBL] [Abstract][Full Text] [Related]
15. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
16. Performance evaluation of Bruker UMIC
Bianco G; Boattini M; Comini S; Gaibani P; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):559-566. PubMed ID: 38240988
[TBL] [Abstract][Full Text] [Related]
17. Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.
Staneck JL; Glenn S; DiPersio JR; Leist PA
J Clin Microbiol; 1989 Oct; 27(10):2277-85. PubMed ID: 2511223
[TBL] [Abstract][Full Text] [Related]
18. Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution.
Hakvoort H; Bovenkamp E; Greenwood-Quaintance KE; Schmidt-Malan SM; Mandrekar JN; Schuetz AN; Patel R
J Clin Microbiol; 2020 Sep; 58(10):. PubMed ID: 32727832
[TBL] [Abstract][Full Text] [Related]
19. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
Takemura M; Wise MG; Hackel MA; Sahm DF; Yamano Y
J Antimicrob Chemother; 2023 Aug; 78(8):2019-2027. PubMed ID: 37390312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
